JACC. Asia最新文献_第10页

Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea 中国、日本和韩国的动脉粥样硬化性心血管疾病风险预测模型

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2025.01.006

Patricia K. Nguyen MD, MBA , Dong Zhao MD, PhD , Tomonori Okamura MD, PhD , Hyeon Chang Kim MD, PhD , Nathan D. Wong PhD , Eugene Yang MD, MS

{"title":"Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea","authors":"Patricia K. Nguyen MD, MBA , Dong Zhao MD, PhD , Tomonori Okamura MD, PhD , Hyeon Chang Kim MD, PhD , Nathan D. Wong PhD , Eugene Yang MD, MS","doi":"10.1016/j.jacasi.2025.01.006","DOIUrl":"10.1016/j.jacasi.2025.01.006","url":null,"abstract":"<div><div>The management of atherosclerotic cardiovascular disease (ASCVD) in the United States is currently based upon large epidemiological studies in primarily non-Hispanic White subjects. Although this strategy provides a uniform approach that is simpler to implement, it may result in inappropriately targeting certain Asian populations for treatment based on inaccurate ASCVD risk estimation. In this state-of-the-art review, we detail the similarities and differences in the prevalence of ASCVD and its risk factors among Chinese, Japanese, and Korean people living in the United States and in their native countries. We highlight the limitations of current risk calculators when applied to East Asian immigrants and summarize risk stratification approaches in China, Japan, and Korea. Our review underscores the need to disaggregate registry, cohort, and clinical trial data by East Asian subgroups, to actively engage these populations in research, and to initiate studies to better define ASCVD risk in East Asian people living in the United States.</div></div>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":"5 3","pages":"Pages 333-349"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Cell Atlas of the Tricuspid Valve Unveils the Matrifibrocyte-Driven Fibrotic Landscape in Functional Tricuspid Regurgitation 三尖瓣单细胞图谱揭示了功能性三尖瓣反流中基质纤维细胞驱动的纤维化景观

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2025.02.010

Onur Kanisicak PhD , Reza Ardehali MD, PhD

引用次数: 0

Full Issue PDF 完整版PDF

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/S2772-3747(25)00140-1

引用次数: 0

The Evolving Landscape of Tricuspid Regurgitation Management 三尖瓣反流管理的发展前景

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2025.02.008

Shih-Hsien Sung MD, PhD

引用次数: 0

Outcomes of Reinitiating Direct Oral Anticoagulants After Intracranial Hemorrhage 颅内出血后重新使用直接口服抗凝剂的结果

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2024.11.008

Yu-Han Wu MS, PharmD , Shin-Yi Lin MS , Fang-Ju Lin PhD , Sung-Chun Tang MD, PhD , Chi-Chuan Wang PhD

{"title":"Outcomes of Reinitiating Direct Oral Anticoagulants After Intracranial Hemorrhage","authors":"Yu-Han Wu MS, PharmD , Shin-Yi Lin MS , Fang-Ju Lin PhD , Sung-Chun Tang MD, PhD , Chi-Chuan Wang PhD","doi":"10.1016/j.jacasi.2024.11.008","DOIUrl":"10.1016/j.jacasi.2024.11.008","url":null,"abstract":"<div><h3>Background</h3><div>Whether or not to reinitiate direct oral anticoagulants (DOACs) in atrial fibrillation patients who survived an antithrombotic agent-associated intracranial hemorrhage (ICH) event remains inconclusive.</div></div><div><h3>Objectives</h3><div>The primary purpose of this study was to investigate the effectiveness and safety of DOACs after ICH, with the secondary objective to explore the optimal timing of DOAC reinitiation.</div></div><div><h3>Methods</h3><div>A sequential target trial emulation study was conducted using the National Health Insurance claims data in Taiwan. We included AF patients receiving antithrombotic therapy who later developed an ICH event between June 2012 and December 2018. Post-ICH DOAC reinitiation status was assessed at 6 consecutive 14-day intervals after discharge. We further stratified our analysis using the stroke severity index to explore the optimal timing of DOAC reinitiation. Study outcomes were all-cause mortality, ICH, and ischemic stroke. Adjusted HRs (aHRs) were estimated using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>DOAC reinitiation was associated with lower risks of all-cause mortality (aHR: 0.73; 95% CI: 0.61-0.88) without increased ICH risk (aHR: 1.21; 95% CI: 0.81-1.80) compared with no antithrombotic therapy after ICH. The ischemic stroke risk after reinitiating DOAC was similar to that with no antithrombotic therapy (aHR: 0.73; 95% CI: 0.47-1.14). Reinitiating DOACs within 14 and 28 days after discharge most benefited patients with low and high ICH severity, respectively.</div></div><div><h3>Conclusions</h3><div>DOAC is associated with lower risk of all-cause mortality. The optimal timing of DOAC reinitiation varies by ICH severity, with later reinitiation recommended for patients with higher ICH severity.</div></div>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":"5 3","pages":"Pages 361-370"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143547847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Status of Tricuspid Valve Interventions in Asia Pacific Region 亚太地区三尖瓣干预的现状

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2024.10.008

Kent Chak-yu So MBChB , Jianqiang Xu MD , Kevin Ka-ho Kam MBChB , Shih-Hsien Sung MD , Krissada Meemook MD , Dee Dee Wang MD , Gilbert H.L. Tang MD, MSc, MBA , Alex Pui-wai Lee MBChB, MD , Yat-yin Lam MBBS

引用次数: 0

Decoding the Indications of Tricuspid Valve Surgery During Aortic Valve Replacement 主动脉瓣置换术中三尖瓣手术的适应症

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2024.11.020

Randolph H.L. Wong MBChB

引用次数: 0

Is Less-Than-Moderate Tricuspid Regurgitation in Patients Undergoing Mitral Valve Surgery Always Benign? 二尖瓣手术患者的中度以下三尖瓣反流总是良性的吗？

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2025.02.005

Sun Kyun Ro MD, PhD

引用次数: 0

Single-Cell Revelations in Tricuspid Valve Remodeling 三尖瓣重构中的单细胞启示

JACC. Asia Pub Date : 2025-03-01 DOI: 10.1016/j.jacasi.2025.02.009

Xinghang Jiang PhD, Jijun Huang PhD